Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

13th DCVMN Conference: DCVMN Must Become Stronger

Published: Monday, November 05, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Through establishing greater cooperation throughout the developing world on vaccine research and development.

The Developing Countries Vaccine Manufacturers Network (DCVMN) can become stronger, especially in establishing cooperation on vaccine research and development.

"DCVMN can be stronger. We have to increase vaccine availability and to improve the quality of vaccine production in developing countries," said out-going DCVMN President Akira Homma at the closing ceremony of 13th DCVMN Annual General Meeting in Kuta Bali.

Homma said DCVMN countries have committed to increasing their efforts to develop vaccines to prevent millions of deaths caused by infectious disease.

Therefore the network members must share the technology and know-how to develop the capacity to produce over 40 vaccine types that would contribute to preventing 2,5 million deaths each year, as estimated by WHO.

Homma also said that Bio Farma is an example of a successful vaccine maker in the developing world not only for being able to produce various types vaccines prequalified by the WHO, but for its initiatives and cooperation on vaccine research with many developing countries as well.

Homma, of Brazil's Bio-Manguinhos-Fiocruz vaccine manufacturer, pointed out the leading role Bio Farma had taken up in 1999 when WHO sponsored steps for the developing countries to jointly develop their capabilities in vaccine research and making.

Homma added that the largest amount of vaccines bought by WHO are produced in the developing countries as they are of the same high quality as those produced in the industrialized world, with lower prices.

The newly-elected president of the DCVMN, Mahendra Suhardono of Bio Farma, expressed his optimism that the organization could be better and become stronger, especially under his leadership for the next two years.

"We commit to increasing cooperation and technology transfer in order to increase vaccine production among developing countries in large quantities and at affordable prices. We don't only want to be sustainable, but we commit to delivering vaccines to more people as well," said Mahendra Suhardono.

Mahendra also stated that Bio Farma has offered cooperation to other developing countries. Two countries which have developed cooperation with Bio Farma are India and South Africa. So far Bio Farma has produced eleven types of vaccine, all WHO pre-qualified.

According to Mahendra, Indonesia has already achieved a "sound, technological platform" in vaccine production and therefore looks forward to establishing cooperation in vaccine research and developments with other DCVMN member countries.

The 13th DCVMN Annual General Meeting in Kuta Bali was attended by more than 100 vaccine experts and high ranking health officials from DCVMN member states and other countries as well as UN bodies.

The meeting also feature presentations and discussions from vaccine experts and government officials from the United States, Europe, Latin America and U.N. bodies.

The 14th DCVMN Annual General Meeting will be held next year in Vietnam.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!